Module 8 - Part 7 of 7

FTAs and IP

Understand the intersection of international trade agreements and intellectual property, including TRIPS-plus provisions, bilateral investment treaties, investor-state disputes, and India's strategic approach to IP in FTA negotiations including RCEP and EU-India discussions.

Duration: 75-90 minutes

7 Key Topics

10 Quiz Questions

Topic 1

IP Chapters in Free Trade Agreements

Modern free trade agreements (FTAs) increasingly include comprehensive intellectual property chapters that go beyond TRIPS requirements. These chapters have become standard in bilateral and regional trade agreements, particularly those involving the United States, European Union, and other developed economies.

Evolution of FTA IP Chapters

The inclusion of IP in trade agreements has evolved significantly:

1990s: TRIPS established as part of WTO - multilateral baseline
2000s: US and EU began including TRIPS-plus provisions in bilateral FTAs
2010s: Mega-regional agreements (TPP, TTIP) with extensive IP chapters
2020s: Continued expansion with digital economy provisions

Key Concept: Why IP in FTAs?

Developed countries include IP chapters in FTAs for several reasons: (1) Raise IP standards beyond TRIPS minimum through bilateral leverage; (2) Lock in higher standards that would be difficult to achieve multilaterally; (3) Create precedents for future negotiations; (4) Protect competitive advantages in innovation-intensive industries; (5) Respond to domestic industry demands for stronger overseas IP protection.

Common Elements of FTA IP Chapters

Patent Provisions

Patent term extensions for regulatory delays, patent linkage for pharmaceuticals, expanded patentable subject matter, limitations on compulsory licensing.

Trademark Provisions

Protection for non-traditional marks (sounds, scents), famous marks protection, domain name dispute resolution procedures.

Extended copyright terms, anti-circumvention rules, ISP liability frameworks, enforcement against online piracy.

Data Exclusivity

Protection for pharmaceutical test data beyond TRIPS Article 39.3 requirements.

Enforcement

Enhanced border measures, statutory damages, criminal penalties, internet enforcement.

Examples of Major FTAs with IP Chapters

USMCA (2020): US-Mexico-Canada Agreement with comprehensive IP chapter
CPTPP (2018): Comprehensive and Progressive Trans-Pacific Partnership
EU-Japan EPA (2019): Economic Partnership Agreement with GI protections
KORUS (2012): US-Korea FTA with extensive pharmaceutical IP provisions
EU-Canada CETA (2017): Comprehensive Economic and Trade Agreement

Topic 2

TRIPS-Plus Provisions

TRIPS-plus provisions are IP obligations that exceed TRIPS requirements. They reduce the flexibilities that TRIPS deliberately preserved for developing countries and can significantly impact access to medicines, technology, and knowledge.

Common TRIPS-Plus Provisions

Patent Term Extensions

Compensation for delays in patent examination or regulatory approval, extending protection beyond 20 years. TRIPS requires only 20 years from filing - no extensions.

Patent Linkage

Requiring drug regulatory authorities to check patent status before approving generic drugs. TRIPS does not require linkage between patent and regulatory systems.

Data Exclusivity

Preventing regulatory authorities from relying on originator's clinical trial data for specified period (5-12 years), blocking generic approvals even without patents.

Extended Copyright Terms

Life plus 70 years (or longer) vs. TRIPS minimum of life plus 50 years. Delays works entering public domain.

Compulsory License Restrictions

Limiting grounds or adding procedural hurdles for compulsory licensing beyond TRIPS Article 31 requirements.

Border Measures Expansion

Extending customs enforcement to exports, in-transit goods, and goods in free trade zones - beyond TRIPS import requirement.

Public Health Concerns

TRIPS-plus provisions have been criticized for their impact on access to medicines. Data exclusivity, patent linkage, and patent term extensions can delay generic competition and keep drug prices high. The UN High-Level Panel on Access to Medicines (2016) recommended that countries refrain from including TRIPS-plus provisions in trade agreements and called for protecting TRIPS flexibilities.

Key Concept: TRIPS Flexibilities vs. TRIPS-Plus

TRIPS was negotiated as a balance between IP protection and public interest flexibilities. Key flexibilities include: freedom to define patentability criteria (enabling Section 3(d)), compulsory licensing (enabling Natco v. Bayer), parallel imports (enabling affordable medicines), and transition periods. TRIPS-plus provisions in FTAs erode these flexibilities, limiting policy space that developing countries fought to preserve in TRIPS negotiations.

Approaches to Avoid TRIPS-Plus

Exclusion: Exclude IP chapter entirely from FTA
Reaffirmation: Include language reaffirming TRIPS flexibilities
Limitations: Limit IP chapter to TRIPS-level obligations
Exceptions: Carve out public health, technology access from TRIPS-plus obligations
Transition periods: Delay implementation of TRIPS-plus provisions

Topic 3

Bilateral Investment Treaties (BITs)

Bilateral Investment Treaties are agreements between two countries providing reciprocal protections for investments. IP rights are increasingly treated as protected "investments" under BITs, creating an additional layer of international protection beyond IP-specific treaties.

IP as Protected Investment

Most BITs define "investment" broadly to include:

Intellectual property rights
Licenses and permits
Goodwill and business reputation
Claims to money or performance with economic value

Key BIT Protections Applicable to IP

Fair and Equitable Treatment (FET)

Obligation to treat investors fairly - may be violated by unexpected changes to IP law, arbitrary enforcement, or denial of IP rights without due process.

Expropriation Protection

Protection against direct and indirect expropriation. Compulsory licensing, revocation, or scope limitation may be challenged as expropriation.

National Treatment

No less favorable treatment than domestic investors. May apply to IP registration, enforcement, and administrative procedures.

Most-Favored Nation

Treatment no less favorable than investors from third countries. Could import protections from other BITs.

Philip Morris v. Australia (PCA Case No. 2012-12)

Philip Morris challenged Australia's tobacco plain packaging laws under the Australia-Hong Kong BIT, claiming expropriation of trademark rights. The tribunal dismissed the case on jurisdictional grounds (restructuring to gain BIT protection). However, the case demonstrated how BITs can be used to challenge public health measures affecting IP rights and created significant "regulatory chill" before resolution.

India's BIT Practice

India has over 80 BITs, though many have been terminated. Key developments:

2015 Model BIT: Revised approach with narrower definitions and protections
IP definition: Includes IP as investment but with limitations
Expropriation: Clarifies regulatory measures not normally expropriatory
Dispute settlement: Requires exhaustion of local remedies for 5 years
Terminations: India has terminated many older BITs to renegotiate

Topic 4

Investor-State Disputes Involving IP

Investor-State Dispute Settlement (ISDS) provisions in BITs and FTAs allow foreign investors to bring arbitration claims directly against host states. Several significant disputes have involved intellectual property rights.

Notable IP-Related ISDS Cases

Eli Lilly v. Canada (ICSID Case No. UNCT/14/2)

Eli Lilly challenged Canadian court decisions invalidating two pharmaceutical patents under NAFTA. Claimed denial of justice and expropriation. Tribunal rejected the claim (2017), finding Canada's promise utility doctrine was not arbitrary.

Philip Morris v. Uruguay (ICSID Case No. ARB/10/7)

Philip Morris challenged Uruguay's tobacco regulations restricting trademark use. Tribunal rejected claims (2016), finding measures were valid exercise of police powers for public health and not expropriatory.

Bridgestone v. Panama (ICSID Case No. ARB/16/34)

Bridgestone challenged Panama's refusal to register its trademark. Case settled (2020) with Panama paying compensation. Demonstrates vulnerability of trademark decisions to ISDS challenge.

Key Concept: Regulatory Chill

"Regulatory chill" refers to governments refraining from legitimate regulation due to fear of ISDS claims. Even unsuccessful claims like Philip Morris v. Australia can cost millions in legal fees and years of uncertainty. Countries may hesitate to implement public health measures, environmental regulations, or IP flexibilities if they fear investor claims. This chilling effect operates even without actual adverse awards.

Key Legal Issues in IP-ISDS Cases

Indirect expropriation: When does regulation affecting IP value constitute compensable expropriation?
Police powers: Can legitimate public interest regulation avoid expropriation claims?
Legitimate expectations: What expectations do IP owners have regarding their rights?
Denial of justice: Can domestic court decisions on IP validity be challenged?
Discrimination: Does differential treatment of foreign IP holders violate BIT protections?

Implications for India

India's IP regime could face ISDS challenges on:

Section 3(d) patentability standard (if challenged as FET violation)
Compulsory licensing decisions (if challenged as expropriation)
Patent revocations (if challenged as denial of justice)
Pre-grant opposition outcomes (if challenged as arbitrary)

India's 2015 Model BIT Response

India's 2015 Model BIT includes provisions designed to limit IP-related ISDS exposure: (1) narrower definition of "investment" requiring substantial business activity; (2) clarification that regulatory measures for public interest are not expropriation; (3) requirement to exhaust local remedies for 5 years before ISDS; (4) exclusion of taxation measures and prudential measures from ISDS.

Topic 5

India's FTA Strategy on IP

India has adopted a cautious approach to IP provisions in FTAs, seeking to preserve TRIPS flexibilities while engaging in trade negotiations. This strategy reflects India's position as a major generic pharmaceutical producer and technology user.

Key Principles of India's Approach

TRIPS compliance: Commit only to TRIPS-level obligations
Preserve flexibilities: Protect compulsory licensing, Section 3(d), parallel imports
Public health priority: Resist provisions that would increase medicine prices
Technology transfer: Seek provisions promoting technology access
Balanced enforcement: Oppose overreaching enforcement measures

Key Concept: India as "Pharmacy of the World"

India supplies over 50% of global demand for generic medicines and 80% of antiretroviral drugs for HIV/AIDS treatment. TRIPS-plus provisions in FTAs could undermine India's generic pharmaceutical industry and impact global access to affordable medicines. This gives India both defensive interests (protecting its industry) and humanitarian justification (protecting global health) for resisting TRIPS-plus provisions.

India's Existing FTAs and IP

India-ASEAN FTA (2010)

Trade in goods agreement with no substantive IP chapter. Services and investment agreements also limited on IP.

India-Japan CEPA (2011)

Includes IP chapter but largely reaffirms TRIPS without significant TRIPS-plus provisions.

India-Korea CEPA (2010)

IP chapter focused on cooperation and enforcement rather than TRIPS-plus standards.

India-Singapore CECA (2005)

Comprehensive agreement but IP provisions remain at TRIPS level.

Negotiating Challenges

Developed country demands: US, EU consistently seek TRIPS-plus commitments
Trade-offs: Pressure to accept IP concessions for market access
Precedent effects: Accepting TRIPS-plus with one partner creates pressure in other negotiations
Domestic lobbying: Pharmaceutical industry influence on both sides
MFN implications: Benefits in bilateral FTAs may need to be extended multilaterally

Topic 6

RCEP and IP Implications

The Regional Comprehensive Economic Partnership (RCEP), signed in November 2020 by 15 Asia-Pacific nations, is the world's largest trade agreement by GDP covered. India withdrew from negotiations in 2019, citing concerns including intellectual property provisions.

RCEP IP Chapter Overview

Chapter 11 of RCEP covers intellectual property with provisions on:

Patents, trademarks, copyrights, designs, GIs
Genetic resources and traditional knowledge
Enforcement measures
Cooperation among IP offices

Key RCEP IP Provisions

TRIPS Reaffirmation

RCEP reaffirms TRIPS obligations and explicitly preserves TRIPS flexibilities including Doha Declaration rights.

No Patent Term Extension

Unlike TPP/CPTPP, RCEP does not require patent term extensions for regulatory delays.

No Patent Linkage

No requirement to link drug regulatory approval to patent status.

Limited Data Exclusivity

No data exclusivity provision for pharmaceuticals - significant for generic industry.

Traditional Knowledge

Includes provisions on genetic resources, traditional knowledge, and folklore - important for India.

Why India Withdrew from RCEP

India's withdrawal from RCEP in November 2019 was driven by multiple concerns: (1) fear of import surge, particularly from China; (2) trade deficit concerns with RCEP countries; (3) inadequate safeguards for services and investment; (4) agricultural sector vulnerabilities; and (5) some IP concerns including enforcement provisions and future ratcheting. While RCEP's IP chapter was more balanced than feared, India was concerned about the overall economic impact and future IP escalation.

Implications of India's Non-Participation

Trade diversion: Supply chains may shift to RCEP members
Rules exclusion: India not part of regional IP standards development
Future accession: Door remains open for India to join later
Alternative strategy: India pursuing bilateral FTAs instead

Topic 7

EU-India FTA Negotiations

The EU-India FTA negotiations, suspended since 2013 and relaunched in 2022, represent one of the most significant ongoing trade negotiations for India. IP has been a major point of contention, reflecting fundamentally different approaches to pharmaceutical patents, data protection, and GI recognition.

History of Negotiations

2007: Negotiations launched
2007-2013: 16 rounds of negotiations
2013: Negotiations suspended over multiple issues including IP
2021: Leaders agree to resume negotiations
2022: Negotiations officially relaunched
Ongoing: Separate tracks for FTA, investment, and GI agreements

Key IP Issues in EU-India Negotiations

Data Exclusivity

EU seeks 8-11 years data exclusivity for pharmaceuticals. India opposes any data exclusivity as it would delay generic approvals. This remains a major stumbling block.

Patent Term Extension

EU may seek extensions for regulatory delays. India opposes extensions beyond TRIPS 20-year term.

Enforcement

EU seeks enhanced enforcement provisions including border measures for in-transit goods. India concerned about seizure of legitimate generic medicines.

Geographical Indications

EU prioritizes GI protection and seeks protection for European GIs (wines, cheeses). India has its own GI interests (Basmati, Darjeeling Tea).

Investment Protection

Being negotiated separately. EU's Investment Court System vs. traditional ISDS. IP as protected investment remains contentious.

The "Generic Seizures" Controversy

In 2008-2009, Dutch customs seized multiple shipments of Indian generic medicines in transit to developing countries, claiming patent infringement under EU law. The medicines were legitimate generics destined for countries where they were legal. This controversy deeply affected EU-India relations and made India wary of EU enforcement demands. India has repeatedly raised this issue and seeks guarantees against seizure of in-transit generics.

Key Concept: Three-Track Approach

The relaunched EU-India negotiations follow a three-track approach: (1) FTA covering trade in goods and services; (2) Standalone Investment Protection Agreement; (3) Geographical Indications Agreement. This separation allows progress on areas of agreement while difficult issues (like IP and investment) are negotiated separately. The GI agreement may be concluded first given mutual interest.

Prospects and Challenges

Mutual interests: Both sides want deeper economic ties
Strategic context: Geopolitical alignment strengthens negotiating momentum
Persistent gaps: Fundamental differences on pharmaceuticals remain
Domestic pressures: Both sides face industry lobbying
Timeline: Ambitious goal but substantive conclusion uncertain

Strategic Considerations for India

India's approach to EU-India FTA should: (1) Firmly resist data exclusivity and patent term extensions that would harm generic industry and public health; (2) Seek strong protections for Indian GIs and market access; (3) Ensure investment agreement does not expose IP regime to ISDS challenges; (4) Include enforceable safeguards against seizure of legitimate in-transit medicines; (5) Preserve full TRIPS flexibilities explicitly in any agreement.

Test Your Knowledge

Part 7 Quiz: FTAs and IP

Answer the following 10 questions to test your understanding of FTAs and IP.

Question 1 of 10

What are "TRIPS-plus" provisions?

A) Provisions that reduce IP protection below TRIPS levels
B) IP obligations that exceed TRIPS minimum requirements
C) Additional enforcement mechanisms under TRIPS
D) WTO dispute settlement procedures

Explanation:

TRIPS-plus provisions are IP obligations in bilateral or regional trade agreements that exceed the minimum standards required by TRIPS. Examples include data exclusivity, patent term extensions, patent linkage, and extended copyright terms. These provisions reduce the flexibilities that TRIPS preserved for member states.

Question 2 of 10

Which of the following is a common TRIPS-plus provision affecting pharmaceuticals?

A) Compulsory licensing
B) Bolar exception
C) Data exclusivity
D) Parallel imports

Explanation:

Data exclusivity is a TRIPS-plus provision that prevents regulatory authorities from relying on the originator's clinical trial data for a specified period, blocking generic approvals even without patents. Compulsory licensing, Bolar exception, and parallel imports are TRIPS flexibilities that TRIPS-plus provisions often restrict.

Question 3 of 10

How do Bilateral Investment Treaties (BITs) relate to IP?

A) IP rights may be protected as "investments" under BITs
B) BITs exclude IP from their scope
C) BITs only cover physical property
D) BITs replace TRIPS for IP protection

Explanation:

Most BITs define "investment" broadly to include intellectual property rights. This means IP owners can potentially challenge government actions affecting their IP (like compulsory licensing or patent revocation) as violations of BIT protections such as fair and equitable treatment or expropriation.

Question 4 of 10

In Philip Morris v. Uruguay, what was the tribunal's decision?

A) Philip Morris won substantial damages
B) Uruguay was required to change its laws
C) The case was dismissed for lack of jurisdiction
D) The tribunal rejected Philip Morris's claims, finding Uruguay's measures were valid public health regulation

Explanation:

The ICSID tribunal rejected Philip Morris's claims in 2016, finding that Uruguay's tobacco regulations (including restrictions on trademark use) were a valid exercise of police powers for public health protection and did not constitute expropriation or violate fair and equitable treatment.

Question 5 of 10

When did India withdraw from RCEP negotiations?

A) 2015
B) 2019
C) 2020
D) India never participated in RCEP

Explanation:

India withdrew from RCEP negotiations in November 2019, just before the agreement was finalized. Concerns included fear of import surge from China, trade deficit issues, inadequate safeguards for services, and some IP-related concerns. The remaining 15 countries signed RCEP in November 2020.

Question 6 of 10

What is "regulatory chill" in the context of ISDS?

A) Governments refraining from regulation due to fear of investor claims
B) Delays in regulatory approval processes
C) Cold relations between regulators and industry
D) Freezing of regulatory proceedings during disputes

Explanation:

Regulatory chill refers to the phenomenon where governments refrain from implementing legitimate regulations (including IP-related public health measures) due to fear of ISDS claims from foreign investors. Even unsuccessful claims can cost millions and years of uncertainty, deterring regulation.

Question 7 of 10

Which is a key feature of India's 2015 Model BIT regarding ISDS?

A) Automatic access to ISDS
B) No ISDS provision at all
C) Requirement to exhaust local remedies for 5 years before ISDS
D) ISDS only for expropriation claims

Explanation:

India's 2015 Model BIT requires investors to exhaust local remedies for at least 5 years before they can bring ISDS claims. This is designed to give Indian courts the first opportunity to address disputes and reduce exposure to international arbitration.

Question 8 of 10

What was the "generic seizures" controversy between India and the EU about?

A) EU seizure of counterfeit goods in India
B) India seizure of EU pharmaceuticals
C) Disputes over generic drug pricing
D) Dutch customs seizing legitimate Indian generic medicines in transit to developing countries

Explanation:

In 2008-2009, Dutch customs seized multiple shipments of legitimate Indian generic medicines transiting through European ports, claiming patent infringement under EU law. The drugs were destined for developing countries where they were legal. This controversy significantly affected EU-India relations and made India wary of EU enforcement demands in FTA negotiations.

Question 9 of 10

What approach are current EU-India negotiations following?

A) Single comprehensive agreement covering everything
B) Three-track approach: FTA, Investment, and GI agreements separately
C) Services-only agreement
D) No formal negotiations ongoing

Explanation:

Question 10 of 10

Which statement about RCEP's IP chapter is correct?

A) RCEP does not require data exclusivity for pharmaceuticals
B) RCEP requires patent term extensions for regulatory delays
C) RCEP requires patent linkage
D) RCEP has the most stringent IP provisions of any FTA

Explanation:

RCEP's IP chapter is notably moderate compared to US FTAs. It does not require data exclusivity for pharmaceuticals, patent term extensions, or patent linkage - all common TRIPS-plus provisions. RCEP explicitly preserves TRIPS flexibilities including Doha Declaration rights, making it more balanced than TPP/CPTPP on pharmaceutical IP.